Literature DB >> 19116449

Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells.

Tai Young Kim1, In Sook Kim, Hyun Soon Jong, Jung Weon Lee, Tae You Kim, Mira Jung, Yung Jue Bang.   

Abstract

We previously reported that trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, induced DLC-1 mRNA expression and accumulated acetylated histones H3 and H4 associated with the DLC-1 promoter in DLC-1 non-expressing gastric cancer cells. In this study, we demonstrated the molecular mechanisms by which TSA induced the DLC-1 gene expression. Treatment of the gastric cancer cells with TSA activates the DLC-1 promoter activity through Sp1 sites located at -219 and -174 relative to the transcription start site. Electrophoretic mobility-shift assay (EMSA) revealed that Sp1 and Sp3 specifically interact with these Sp1 sites and showed that TSA did not change their binding activities. The ectopic expression of Sp1, but not Sp3, enhances the DLC-1 promoter responsiveness by TSA. Furthermore, the TSA-induced DLC-1 promoter activity was increased by p300 expression and reduced by knockdown of p300. These results demonstrated the requirement of specific Sp1 sites and dependence of Sp1 and p300 for TSA-mediated activation of DLC-1 promoter.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19116449      PMCID: PMC2679347          DOI: 10.3858/emm.2008.40.6.639

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  32 in total

Review 1.  Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics.

Authors:  Anton Eberharter; Peter B Becker
Journal:  EMBO Rep       Date:  2002-03       Impact factor: 8.807

2.  p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor.

Authors:  H Xiao; T Hasegawa; K Isobe
Journal:  J Biol Chem       Date:  2000-01-14       Impact factor: 5.157

Review 3.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

4.  DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1.

Authors:  I O Ng; Z D Liang; L Cao; T K Lee
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

5.  The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein.

Authors:  Gang Liu; Tian Xia; Xinbin Chen
Journal:  J Biol Chem       Date:  2003-02-27       Impact factor: 5.157

6.  Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers.

Authors:  Bao-Zhu Yuan; Marian E Durkin; Nicholas C Popescu
Journal:  Cancer Genet Cytogenet       Date:  2003-01-15

7.  Inhibition of DLC-1 gene expression by RNA interference in the colon cancer LoVo cell line.

Authors:  Yueling Jin; Xiaoqiang Tian; Yanfang Shang; Peiling Huang
Journal:  Oncol Rep       Date:  2008-03       Impact factor: 3.906

8.  Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.

Authors:  Shujie Zhao; Kolaparthi Venkatasubbarao; Senlin Li; James W Freeman
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity.

Authors:  Bao-Zhu Yuan; Xiaoling Zhou; Marian E Durkin; Drazen B Zimonjic; Katrin Gumundsdottir; Jorunn E Eyfjord; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Oncogene       Date:  2003-01-23       Impact factor: 9.867

10.  DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms.

Authors:  Kevin D Healy; Louis Hodgson; Tai-Young Kim; Adam Shutes; Savitri Maddileti; Rudolph L Juliano; Klaus M Hahn; T Kendall Harden; Yung-Jue Bang; Channing J Der
Journal:  Mol Carcinog       Date:  2008-05       Impact factor: 4.784

View more
  5 in total

1.  Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.

Authors:  Xiaoling Zhou; Xu-Yu Yang; Nicholas C Popescu
Journal:  Biochem Biophys Res Commun       Date:  2012-03-07       Impact factor: 3.575

2.  Interplay between PKCδ and Sp1 on histone deacetylase inhibitor-mediated Epstein-Barr virus reactivation.

Authors:  Pei-Fang Tsai; Sue-Jane Lin; Pei-Lun Weng; Shu-Chun Tsai; Jiun-Han Lin; Ya-Ching Chou; Ching-Hwa Tsai
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

Review 3.  Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.

Authors:  Anderly C Chueh; Janson W T Tse; Lars Tögel; John M Mariadason
Journal:  Antioxid Redox Signal       Date:  2014-03-27       Impact factor: 8.401

Review 4.  Learning therapeutic lessons from metastasis suppressor proteins.

Authors:  Steven Christopher Smith; Dan Theodorescu
Journal:  Nat Rev Cancer       Date:  2009-02-26       Impact factor: 60.716

Review 5.  Epigenetic roles in the malignant transformation of gastric mucosal cells.

Authors:  Jun Tie; Xiangyuan Zhang; Daiming Fan
Journal:  Cell Mol Life Sci       Date:  2016-07-27       Impact factor: 9.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.